Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235502 | 0.73 | ALDH1A1 (0.35) | ALDH1A1LMNAHTTPIP4K2CNOTUM | |
| SCHEMBL29723106 | 0.73 | ALDH1A1 (0.35) | ALDH1A1LMNAHTTPIP4K2CNOTUM | |
| SCHEMBL12261327 | 0.72 | LIMK1 (0.41) | ALDH1A1HSD17B10 | |
| SCHEMBL23519908 | 0.66 | NPC1 (0.47) | ALDH1A1LMNANOTUMTP53HSD17B10 | |
| SCHEMBL2232351 | 0.65 | PDE4B (0.33) | ALDH1A1LMNATP53HSD17B10 | |
| SCHEMBL2233009 | 0.65 | ALDH1A1 (0.33) | ALDH1A1LMNANOTUMTP53HSD17B10 | |
| SCHEMBL12432761 | 0.64 | TP53 (0.36) | ALDH1A1LMNATP53HSD17B10 | |
| SCHEMBL2395594 | 0.64 | IRAK4 (0.38) | ALDH1A1LMNAHTTTP53HSD17B10 | |
| SCHEMBL14731307 | 0.63 | ALDH1A1 (0.33) | ALDH1A1LMNANOTUMTP53HSD17B10 | |
| SCHEMBL4472087 | 0.63 | ALDH1A1 (0.55) | ALDH1A1LMNAHTTTP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2719701-B1 | Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2719701-B1 | Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9156872-B2 | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| EP-2719701-A1 | methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES, INC. (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2719701-A1 | methods for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES, INC. (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2396340-B1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012142075-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-2396340-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2011-12-21 | — | — | EP | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | ALDH1A1 3094/4885LMNA 1447/4885HTT 3036/4885 |
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ADAR, SLC29A1, SLC28A1 | ALDH1A1 271/4885LMNA 1948/4885HTT 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.